| scholarly article | Q13442814 |
| P50 | author | Christoph Mayer | Q42735161 |
| P2093 | author name string | Marina Borisova | |
| Jonathan Gisin | |||
| P2860 | cites work | Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin Resistance | Q26853135 |
| Resistance to antibiotics targeted to the bacterial cell wall | Q26859841 | ||
| Crystal structure of a genomically encoded fosfomycin resistance protein (FosA) at 1.19 A resolution by MAD phasing off the L-III edge of Tl(+) | Q27639636 | ||
| Studies on transformation of Escherichia coli with plasmids | Q27860598 | ||
| Common Virulence Factors for Bacterial Pathogenicity in Plants and Animals | Q28292772 | ||
| The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa | Q28492495 | ||
| Genetic determinants involved in the susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics | Q28493162 | ||
| An ordered, nonredundant library of Pseudomonas aeruginosa strain PA14 transposon insertion mutants | Q29614860 | ||
| High efficiency transformation of Escherichia coli with plasmids | Q29616589 | ||
| A cell wall recycling shortcut that bypasses peptidoglycan de novo biosynthesis | Q31811697 | ||
| Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis | Q33982025 | ||
| The mechanism of action of fosfomycin (phosphonomycin) | Q34214482 | ||
| Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection | Q34233774 | ||
| Pharmacology of polymyxins: new insights into an 'old' class of antibiotics | Q34346283 | ||
| Determinants of intrinsic aminoglycoside resistance in Pseudomonas aeruginosa | Q34386310 | ||
| Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections | Q34421301 | ||
| 'Old' antibiotics for emerging multidrug-resistant bacteria | Q34565772 | ||
| Fosfomycin: use beyond urinary tract and gastrointestinal infections | Q34774778 | ||
| Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods | Q35191584 | ||
| Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms | Q36364199 | ||
| Structure of fosfomycin resistance protein FosA from transposon Tn2921. | Q36526557 | ||
| Outer membrane proteins of Pseudomonas | Q36604324 | ||
| How bacteria consume their own exoskeletons (turnover and recycling of cell wall peptidoglycan) | Q37183911 | ||
| Fosfomycin: an old--new antibiotic | Q37931369 | ||
| The revival of fosfomycin | Q37938425 | ||
| Will new antimicrobials overcome resistance among Gram-negatives? | Q37942654 | ||
| Providing β-lactams a helping hand: targeting the AmpC β-lactamase induction pathway. | Q37961906 | ||
| The intrinsic resistome of bacterial pathogens | Q38103861 | ||
| Cryo-Transmission Electron Microscopy of Frozen-Hydrated Sections ofEscherichia coliandPseudomonas aeruginosa | Q39997774 | ||
| Role of ciprofloxacin in its synergistic effect with fosfomycin on drug-resistant strains of Pseudomonas aeruginosa | Q42170768 | ||
| NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, in Pseudomonas aeruginosa | Q42430253 | ||
| Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis | Q42550334 | ||
| Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay | Q43961938 | ||
| Phosphonoformate: a minimal transition state analogue inhibitor of the fosfomycin resistance protein, FosA. | Q45123405 | ||
| Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. | Q46795441 | ||
| Cytosolic intermediates for cell wall biosynthesis and degradation control inducible beta-lactam resistance in gram-negative bacteria. | Q54568935 | ||
| Characterization of a Cys115 to Asp substitution in the Escherichia coli cell wall biosynthetic enzyme UDP-GlcNAc enolpyruvyl transferase (MurA) that confers resistance to inactivation by the antibiotic fosfomycin. | Q54590227 | ||
| Correlation between the effects of fosfomycin and chloramphenicol on Escherichia coli. | Q54720071 | ||
| Phosphonomycin, a New Antibiotic Produced by Strains of Streptomyces | Q72475705 | ||
| Genetic recombination in Pseudomonas aeruginosa | Q73881599 | ||
| P433 | issue | 3 | |
| P921 | main subject | Pseudomonas aeruginosa | Q31856 |
| N-acetyl-(α/β)-muramic acid | Q27109407 | ||
| P304 | page(s) | 231-237 | |
| P577 | publication date | 2014-05-12 | |
| P1433 | published in | Microbial Drug Resistance | Q15750500 |
| P1476 | title | Blocking peptidoglycan recycling in Pseudomonas aeruginosa attenuates intrinsic resistance to fosfomycin. | |
| P478 | volume | 20 |
| Q38841863 | Bioconversion of anhydrosugars: Emerging concepts and strategies |
| Q88918474 | Cell-Wall Recycling of the Gram-Negative Bacteria and the Nexus to Antibiotic Resistance |
| Q31811695 | Crystal Structure of the N-Acetylmuramic Acid α-1-Phosphate (MurNAc-α1-P) Uridylyltransferase MurU, a Minimal Sugar Nucleotidyltransferase and Potential Drug Target Enzyme in Gram-negative Pathogens |
| Q36675246 | Fosfomycin |
| Q91823267 | Identification of Drug Resistance Determinants in a Clinical Isolate of Pseudomonas aeruginosa by High-Density Transposon Mutagenesis |
| Q36326129 | Identification of MupP as a New Peptidoglycan Recycling Factor and Antibiotic Resistance Determinant in Pseudomonas aeruginosa |
| Q49422952 | N-Acetylmuramic Acid (MurNAc) Auxotrophy of the Oral Pathogen Tannerella forsythia: Characterization of a MurNAc Kinase and Analysis of Its Role in Cell Wall Metabolism |
| Q64898853 | Oral and intravenous fosfomycin in complicated urinary tract infections. |
| Q58728835 | Oxygen Limitation Enhances the Antimicrobial Activity of Fosfomycin in Following Overexpression of Which Encodes Glycerol-3-Phosphate/Fosfomycin Symporter |
| Q64106873 | Peptidoglycan Muropeptides: Release, Perception, and Functions as Signaling Molecules |
| Q39301500 | Peptidoglycan Recycling in Gram-Positive Bacteria Is Crucial for Survival in Stationary Phase |
| Q93059794 | Peptidoglycan-type analysis of the N-acetylmuramic acid auxotrophic oral pathogen Tannerella forsythia and reclassification of the peptidoglycan-type of Porphyromonas gingivalis |
| Q100465261 | Proximate and ultimate causes of the bactericidal action of antibiotics |
| Q40401711 | Synergistic activity of fosfomycin, β-lactams and peptidoglycan recycling inhibition against Pseudomonas aeruginosa |
| Q31811699 | The N-Acetylmuramic Acid 6-Phosphate Phosphatase MupP Completes the Pseudomonas Peptidoglycan Recycling Pathway Leading to Intrinsic Fosfomycin Resistance |
| Q38852902 | The analysis of the antibiotic resistome offers new opportunities for therapeutic intervention |
| Q64984613 | Tobramycin-Linked Efflux Pump Inhibitor Conjugates Synergize Fluoroquinolones, Rifampicin and Fosfomycin against Multidrug-Resistant Pseudomonas aeruginosa. |
| Q40625268 | Two Small RNAs Conserved in Enterobacteriaceae Provide Intrinsic Resistance to Antibiotics Targeting the Cell Wall Biosynthesis Enzyme Glucosamine-6-Phosphate Synthase |
| Q35105960 | Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa |
Search more.